Logo image of GMAB

GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis

NASDAQ:GMAB - Nasdaq - US3723032062 - ADR - Currency: USD

21.4  -0.46 (-2.1%)

After market: 21.4 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to GMAB. GMAB was compared to 557 industry peers in the Biotechnology industry. While GMAB has a great profitability rating, there are some minor concerns on its financial health. GMAB is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year GMAB was profitable.
In the past year GMAB has reported a negative cash flow from operations.
Each year in the past 5 years GMAB has been profitable.
Each year in the past 5 years GMAB had a positive operating cash flow.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

1.2 Ratios

Looking at the Return On Assets, with a value of 36.16%, GMAB belongs to the top of the industry, outperforming 98.74% of the companies in the same industry.
Looking at the Return On Equity, with a value of 44.97%, GMAB belongs to the top of the industry, outperforming 98.38% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 37.15%, GMAB belongs to the top of the industry, outperforming 99.46% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMAB is in line with the industry average of 14.78%.
The 3 year average ROIC (15.19%) for GMAB is below the current ROIC(37.15%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 36.16%
ROE 44.97%
ROIC 37.15%
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

Looking at the Profit Margin, with a value of 29.99%, GMAB belongs to the top of the industry, outperforming 96.95% of the companies in the same industry.
GMAB's Profit Margin has declined in the last couple of years.
GMAB's Operating Margin of 33.50% is amongst the best of the industry. GMAB outperforms 98.03% of its industry peers.
GMAB's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 95.91%, GMAB belongs to the best of the industry, outperforming 95.33% of the companies in the same industry.
In the last couple of years the Gross Margin of GMAB has declined.
Industry RankSector Rank
OM 33.5%
PM (TTM) 29.99%
GM 95.91%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

6

2. Health

2.1 Basic Checks

GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
GMAB has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, GMAB has less shares outstanding
The debt/assets ratio for GMAB is higher compared to a year ago.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

An Altman-Z score of 43.81 indicates that GMAB is not in any danger for bankruptcy at the moment.
GMAB's Altman-Z score of 43.81 is amongst the best of the industry. GMAB outperforms 98.03% of its industry peers.
GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
GMAB has a Debt to Equity ratio (0.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 43.81
ROIC/WACC5.37
WACC6.92%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.3 Liquidity

GMAB has a Current Ratio of 5.34. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
GMAB's Current ratio of 5.34 is in line compared to the rest of the industry. GMAB outperforms 56.01% of its industry peers.
A Quick Ratio of 5.32 indicates that GMAB has no problem at all paying its short term obligations.
The Quick ratio of GMAB (5.32) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.34
Quick Ratio 5.32
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for GMAB have decreased strongly by -35.87% in the last year.
Measured over the past years, GMAB shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.75% on average per year.
GMAB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -55.29%.
GMAB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.38% yearly.
EPS 1Y (TTM)-35.87%
EPS 3Y15.53%
EPS 5Y15.75%
EPS Q2Q%-84.89%
Revenue 1Y (TTM)-55.29%
Revenue growth 3Y-26.96%
Revenue growth 5Y-9.38%
Sales Q2Q%-82.74%

3.2 Future

GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.22% yearly.
Based on estimates for the next years, GMAB will show a quite strong growth in Revenue. The Revenue will grow by 11.76% on average per year.
EPS Next Y51.17%
EPS Next 2Y34.57%
EPS Next 3Y30.51%
EPS Next 5Y18.22%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y11.76%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10B 20B 30B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15 20

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 24.88, which indicates a rather expensive current valuation of GMAB.
Based on the Price/Earnings ratio, GMAB is valued cheaper than 94.79% of the companies in the same industry.
GMAB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.30.
The Price/Forward Earnings ratio is 10.34, which indicates a very decent valuation of GMAB.
96.23% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.76. GMAB is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 24.88
Fwd PE 10.34
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 93.18% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 29.79
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
GMAB has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as GMAB's earnings are expected to grow with 30.51% in the coming years.
PEG (NY)0.49
PEG (5Y)1.58
EPS Next 2Y34.57%
EPS Next 3Y30.51%

More info and screens

0

5. Dividend

5.1 Amount

GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENMAB A/S -SP ADR

NASDAQ:GMAB (7/11/2025, 8:18:45 PM)

After market: 21.4 0 (0%)

21.4

-0.46 (-2.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners35.41%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.19B
Analysts77.24
Price Target111.85 (422.66%)
Short Float %0.38%
Short Ratio1.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.16%
Min EPS beat(2)49.64%
Max EPS beat(2)134.67%
EPS beat(4)3
Avg EPS beat(4)44.12%
Min EPS beat(4)-11.29%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.35%
EPS beat(12)8
Avg EPS beat(12)28.68%
EPS beat(16)11
Avg EPS beat(16)28.52%
Revenue beat(2)1
Avg Revenue beat(2)-2.9%
Min Revenue beat(2)-7.66%
Max Revenue beat(2)1.87%
Revenue beat(4)2
Avg Revenue beat(4)-1.37%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)4.57%
Revenue beat(8)6
Avg Revenue beat(8)0.63%
Revenue beat(12)10
Avg Revenue beat(12)2.66%
Revenue beat(16)14
Avg Revenue beat(16)3.42%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-84.64%
EPS NQ rev (3m)-82.27%
EPS NY rev (1m)-0.05%
EPS NY rev (3m)4.24%
Revenue NQ rev (1m)-84.98%
Revenue NQ rev (3m)-85.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.77%
Valuation
Industry RankSector Rank
PE 24.88
Fwd PE 10.34
P/S 10.58
P/FCF N/A
P/OCF N/A
P/B 15.87
P/tB 26.38
EV/EBITDA 29.79
EPS(TTM)0.86
EY4.02%
EPS(NY)2.07
Fwd EY9.68%
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS2.02
BVpS1.35
TBVpS0.81
PEG (NY)0.49
PEG (5Y)1.58
Profitability
Industry RankSector Rank
ROA 36.16%
ROE 44.97%
ROCE 45.64%
ROIC 37.15%
ROICexc 83.17%
ROICexgc 439.3%
OM 33.5%
PM (TTM) 29.99%
GM 95.91%
FCFM N/A
ROA(3y)15.85%
ROA(5y)16.41%
ROE(3y)18.38%
ROE(5y)18.67%
ROIC(3y)15.19%
ROIC(5y)16.37%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)18.66%
ROCE(5y)20.11%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score6
Asset Turnover1.21
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA 0.05
Cap/Depr 76.79%
Cap/Sales 0.61%
Interest Coverage 8004.34
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.34
Quick Ratio 5.32
Altman-Z 43.81
F-Score6
WACC6.92%
ROIC/WACC5.37
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-35.87%
EPS 3Y15.53%
EPS 5Y15.75%
EPS Q2Q%-84.89%
EPS Next Y51.17%
EPS Next 2Y34.57%
EPS Next 3Y30.51%
EPS Next 5Y18.22%
Revenue 1Y (TTM)-55.29%
Revenue growth 3Y-26.96%
Revenue growth 5Y-9.38%
Sales Q2Q%-82.74%
Revenue Next Year15.81%
Revenue Next 2Y15.31%
Revenue Next 3Y14.81%
Revenue Next 5Y11.76%
EBIT growth 1Y-53.2%
EBIT growth 3Y-28.52%
EBIT growth 5Y-16.38%
EBIT Next Year31.35%
EBIT Next 3Y25.55%
EBIT Next 5Y13.52%
FCF growth 1Y-101.46%
FCF growth 3Y-16.81%
FCF growth 5Y-1.31%
OCF growth 1Y-100.64%
OCF growth 3Y-19%
OCF growth 5Y-2.24%